BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Armstrong MJ, Gohar F, Dhaliwal A, Nightingale P, Baker G, Greaves D, Mangat K, Zia Z, Karkhanis S, Olliff S, Mehrzad H, Steeds RP, Tripathi D. Diastolic dysfunction on echocardiography does not predict survival after transjugular intrahepatic portosystemic stent-shunt in patients with cirrhosis. Aliment Pharmacol Ther 2019;49:797-806. [DOI: 10.1111/apt.15164] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Tripathi D, Stanley AJ, Hayes PC, Travis S, Armstrong MJ, Tsochatzis EA, Rowe IA, Roslund N, Ireland H, Lomax M, Leithead JA, Mehrzad H, Aspinall RJ, McDonagh J, Patch D. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. Gut 2020;69:1173-92. [PMID: 32114503 DOI: 10.1136/gutjnl-2019-320221] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
2 Jansen C, Trebicka J. Editorial: diastolic dysfunction seems not to be decisive for survival after transjugular intrahepatic portosystemic stent-shunt. Aliment Pharmacol Ther 2019;49:1101-2. [PMID: 30920049 DOI: 10.1111/apt.15221] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Rajesh S, George T, Philips CA, Ahamed R, Kumbar S, Mohan N, Mohanan M, Augustine P. Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update. World J Gastroenterol 2020; 26(37): 5561-5596 [PMID: 33088154 DOI: 10.3748/wjg.v26.i37.5561] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Steib CJ, Li H, Zhang J, Mayerle J, Ricke J, Gerbes AL, Meyer C, Zipprich A, Trebicka J. Transjugular intrahepatic portosystemic shunt for patients with liver cirrhosis: survey evaluating indications, standardization of procedures and anticoagulation in 43 German hospitals. European Journal of Gastroenterology & Hepatology 2020;32:1179-85. [DOI: 10.1097/meg.0000000000001628] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
5 Praktiknjo M, Abu-Omar J, Chang J, Thomas D, Jansen C, Kupczyk P, Schepis F, Garcia-Pagan JC, Merli M, Meyer C, Strassburg CP, Pieper CC, Trebicka J. Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation. JHEP Rep 2021;3:100264. [PMID: 34013182 DOI: 10.1016/j.jhepr.2021.100264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
6 García-Pagán JC, Saffo S, Mandorfer M, Garcia-Tsao G. Where does TIPS fit in the management of patients with cirrhosis? JHEP Rep 2020;2:100122. [PMID: 32671331 DOI: 10.1016/j.jhepr.2020.100122] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
7 Yuan S, Yang X, Chen J, Zhao S, Xu J, Liang C. Letter: predictors of survival in patients undergoing transjugular intrahepatic portosystemic shunt-what should we assess by ultrasound? Aliment Pharmacol Ther 2019;50:841-2. [PMID: 31532562 DOI: 10.1111/apt.15468] [Reference Citation Analysis]